Barclays analyst Andrew Mok lowered the firm’s price target on Acadia Healthcare to $91 from $100 and keeps an Overweight rating on the shares. Despite expected soft volumes, continued pricing strength and well-controlled labor costs drove a modest EBITDA beat in Q1, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- ACHC Upcoming Earnings Report: What to Expect?
- Acadia Healthcare upgraded to Hold from Sell at Deutsche Bank
- Acadia Healthcare appoints Stephanie Eken as Chief Medical Officer
- Acadia Healthcare, Uber partner to provide patients access to transportation
- Acadia Healthcare acquires three treatment centers in North Carolina
